Literature DB >> 20688135

Specific determinants of conantokins that dictate their selectivity for the NR2B subunit of N-methyl-D-aspartate receptors.

Z Sheng1, M Prorok, F J Castellino.   

Abstract

Conantokins are naturally-occurring small peptide antagonists of ion flow through NMDA/glycine activated-N-methyl-d-aspartate receptor (NMDAR) ion channels. One member of the conantokin family, conantokin (con)-G, a 17-residue peptide, is selective for NMDARs containing the N-methyl-d-aspartate receptor subunit 2 B (NR2B), whereas the homologous peptides, con-T and con-R, show broader selectivity for NR2 subunits. In this study, con-G, con-R, and con-T variants were chemically synthesized and employed to investigate their subunit selectivities as inhibitors of agonist-evoked ion currents in human embryonic kidney-293 (HEK-293) cells expressing various combinations of NMDAR subunits that contain NR1a or NR1b combined with NR2A or NR2B. Using truncation and point mutants, as well as chimeric conantokins, we determined that the N-terminus of con-G contains all the determinants for NR2B selectivity. With this information, a large number of (con) variants were synthesized and used to establish minimal sequence determinants for selectivity. Tyr at position 5 broadens the NR2 selectivity, and recovery of NR2B selectivity in Tyr5 peptides was achieved by incorporating Ala or Gly at position 8. NR2B selectivity in con-R can be conferred through deletion of the Ala at position 10, thereby shifting the γ-carboxyglutamate (Gla) from position 11 to position 10, where a Gla naturally occurs in con-G and con-T. The nature of the amino acid at position 6 is also linked to subunit selectivity. Our studies suggest that the molecular determinants of conantokins that dictate NMDAR subunit selectivity are housed in specific residues of the N-termini of these peptides. Thus, it is possible to engineer desired NMDAR functional properties into conantokin-based peptides.
Copyright © 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688135      PMCID: PMC2939254          DOI: 10.1016/j.neuroscience.2010.07.056

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  30 in total

1.  Structure-function relationships of the NMDA receptor antagonist peptide, conantokin-R.

Authors:  T Blandl; S E Warder; M Prorok; F J Castellino
Journal:  FEBS Lett       Date:  2000-03-24       Impact factor: 4.124

2.  Localization of N-methyl-D-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats.

Authors:  Q P Ma; R J Hargreaves
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

3.  Sequence requirements for the N-methyl-D-aspartate receptor antagonist activity of conantokin-R.

Authors:  T Blandl; J Zajicek; M Prorok; F J Castellino
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

4.  Conantokin-P, an unusual conantokin with a long disulfide loop.

Authors:  Konkallu Hanumae Gowd; Vernon Twede; Maren Watkins; K S Krishnan; Russell W Teichert; Grzegorz Bulaj; Baldomero M Olivera
Journal:  Toxicon       Date:  2008-06-03       Impact factor: 3.033

5.  Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors.

Authors:  S D Donevan; R T McCabe
Journal:  Mol Pharmacol       Date:  2000-09       Impact factor: 4.436

6.  A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury.

Authors:  R E Merchant; M R Bullock; C A Carmack; A K Shah; K D Wilner; G Ko; S A Williams
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

7.  Amino acid determinants for NMDA receptor inhibition by conantokin-T.

Authors:  S E Warder; T Blandl; R C Klein; F J Castellino; M Prorok
Journal:  J Neurochem       Date:  2001-05       Impact factor: 5.372

8.  In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus.

Authors:  H S White; R T McCabe; H Armstrong; S D Donevan; L J Cruz; F C Abogadie; J Torres; J E Rivier; I Paarmann; M Hollmann; B M Olivera
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

9.  Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors.

Authors:  Russell W Teichert; Elsie C Jimenez; Vernon Twede; Maren Watkins; Michael Hollmann; Grzegorz Bulaj; Baldomero M Olivera
Journal:  J Biol Chem       Date:  2007-10-25       Impact factor: 5.157

10.  Conantokin-Br from Conus brettinghami and selectivity determinants for the NR2D subunit of the NMDA receptor.

Authors:  Vernon D Twede; Russell W Teichert; Craig S Walker; Paweł Gruszczyński; Rajmund Kaźmierkiewicz; Grzegorz Bulaj; Baldomero M Olivera
Journal:  Biochemistry       Date:  2009-05-19       Impact factor: 3.162

View more
  8 in total

1.  Conantokins derived from the Asprella clade impart conRl-B, an N-methyl d-aspartate receptor antagonist with a unique selectivity profile for NR2B subunits.

Authors:  Konkallu Hanumae Gowd; Tiffany S Han; Vernon Twede; Joanna Gajewiak; Misty D Smith; Maren Watkins; Randall J Platt; Gabriela Toledo; H Steve White; Baldomero M Olivera; Grzegorz Bulaj
Journal:  Biochemistry       Date:  2012-05-30       Impact factor: 3.162

2.  Pharmacology of triheteromeric N-Methyl-D-Aspartate Receptors.

Authors:  John Cheriyan; Rashna D Balsara; Kasper B Hansen; Francis J Castellino
Journal:  Neurosci Lett       Date:  2016-02-23       Impact factor: 3.046

3.  Hydroxyproline-induced Helical Disruption in Conantokin Rl-B Affects Subunit-selective Antagonistic Activities toward Ion Channels of N-Methyl-d-aspartate Receptors.

Authors:  Shailaja Kunda; Yue Yuan; Rashna D Balsara; Jaroslav Zajicek; Francis J Castellino
Journal:  J Biol Chem       Date:  2015-06-05       Impact factor: 5.157

4.  From molecular phylogeny towards differentiating pharmacology for NMDA receptor subtypes.

Authors:  Randall J Platt; Kigen J Curtice; Vernon D Twede; Maren Watkins; Paweł Gruszczyński; Grzegorz Bulaj; Martin P Horvath; Baldomero M Olivera
Journal:  Toxicon       Date:  2014-02-07       Impact factor: 3.033

Review 5.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

Review 6.  From toxins targeting ligand gated ion channels to therapeutic molecules.

Authors:  Adak Nasiripourdori; Valérie Taly; Thomas Grutter; Antoine Taly
Journal:  Toxins (Basel)       Date:  2011-03-21       Impact factor: 4.546

7.  In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer's disease.

Authors:  Maleeha Waqar; Sidra Batool
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2017-09-20

8.  Antagonistic action on NMDA/GluN2B mediated currents of two peptides that were conantokin-G structure-based designed.

Authors:  Edwin A Reyes-Guzman; Nohora Vega-Castro; Edgar A Reyes-Montaño; Esperanza Recio-Pinto
Journal:  BMC Neurosci       Date:  2017-05-16       Impact factor: 3.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.